Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
16 hedge funds and large institutions have $1.49M invested in Statera Biopharma, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
11% less funds holding
Funds holding: 18 → 16 (-2)
16% less capital invested
Capital invested by funds: $1.77M → $1.49M (-$282K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$65.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$47.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$42.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$42K |
| 2 |
BlackRock
New York
|
-$10.8K |
| 3 |
WA
Winfield Associates
Cleveland,
Ohio
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $797K | +$65.6K | +18,600 | +8% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $514K | +$46.2K | +13,101 | +8% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $50K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $41K | +$47.6K | +13,501 | New |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $36K | +$42.3K | +11,987 | New |
|
|
6
BlackRock
New York
| $35K | -$10.8K | -3,075 | -21% |
|
|
7
UBS Group
Zurich,
Switzerland
| $12K | +$13.9K | +3,930 | New |
|
|
IA
8
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
PAM
9
Panagora Asset Management
Boston,
Massachusetts
| – | -$42K | -10,427 | Closed |
|
|
WA
10
Winfield Associates
Cleveland,
Ohio
| – | -$3K | -500 | Closed |
|
STAB Hedge Fund Activity: Q1 2018 in Review
16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2018, worth a combined $1.49M — down 16% from $1.77M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of STAB and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $65.6K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $42K sold.
- 16 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2018, down from 18 in Q4 2017.
- Funds reported $1.49M of Statera Biopharma, Inc. Common Stock stock for Q1 2018, down 16% quarter-over-quarter.
- 3 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2018 and 5 closed out, a net change of -2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2018 was Renaissance Technologies, an estimated $65.6K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2018 was Panagora Asset Management, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2018.